Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gazhaluoshu
- Development stage
- Unknown
- Lead developer
- Inner Mongolia Fudan Mengyao Biotechnology
- Administration
- Topical
01
Overview
Gazhaluoshu is a Traditional Mongolian Medicine (TMM) gel formulation developed by Inner Mongolia Fudan Mengyao Biotechnology for the treatment of diabetic peripheral neuropathy (DPN) and diabetic painful neuropathy. The drug is designed to address the "vessel obstruction syndrome" (脉络痹阻证) commonly associated with DPN in traditional medicine frameworks. It is administered topically as a gel to improve neurological symptoms and signs. Clinical development in China has included Phase II trials (such as CTR20140484) to evaluate its safety and therapeutic efficacy in patients suffering from DPN-related pain and sensory loss.
- Brand names
- Gazhaluoshu
- Other names
- 嘎扎络舒Gazhaluoshu Gel
Beyond the preview
Go deeper on Gazhaluoshu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gazhaluoshu.